公开(公告)号：EP0796489B1

公开(公告)日：1999-05-06

申请号：EP95938368.8

申请日：1995-11-27

申请人： Fink, Fleming K. ,  Hartmann, Uwe ,  Hermansen, Kjeld ,  Rubak, Per

发明人： Fink, Fleming K. ,  Hartmann, Uwe ,  Hermansen, Kjeld ,  Rubak, Per

IPC分类号： G10L3/00

CPC分类号： G10L21/0208 ,  G10L21/003 ,  G10L21/0364 ,  G10L21/04 ,  G10L25/12

公开(公告)号：EP0796489A2

公开(公告)日：1997-09-24

申请号：EP95938368.0

申请日：1995-11-27

申请人： Fink, Fleming K. ,  Hartmann, Uwe ,  Hermansen, Kjeld ,  Rubak, Per

发明人： Fink, Fleming K. ,  Hartmann, Uwe ,  Hermansen, Kjeld ,  Rubak, Per

IPC分类号： G10L19 ,  G10L21

CPC分类号： G10L21/0208 ,  G10L21/003 ,  G10L21/0364 ,  G10L21/04 ,  G10L25/12

摘要： Transformation of a speech signal comprises separating the speech signal into two signal parts (a, b), where (a) represents the quasistationary part and (b) the transient part of the signal. The signal (b) is filtered inversely and is supplied in parallel to a transient detector and a pitch manipulator, while the signal (a) is subjected to a spectral analysis. The transformation circuit of the invention permits well-defined manipulation of any speech signal, which is advantageous partly for hearing-impaired persons, partly for persons having normal hearing ability in noisy environments. Finally, the circuit of the invention has been found to be extremely expedient for synthesizing well-defined sounds, which is of great importance in the control of hearing aids (hearing loss simulator).

公开(公告)号：EP1361870A2

公开(公告)日：2003-11-19

申请号：EP01957770.9

申请日：2001-07-31

申请人： Nutri Pharma ASA ,  Hermansen, Kjeld ,  Gregersen, Soeren ,  Jeppesen, Per Bendix

发明人： HERMANSEN, Kjeld ,  GREGERSEN, Soren ,  JEPPESEN, Per, Bendix ,  HOIE, Lars, H.

IPC分类号： A61K31/00 ,  A61K31/19 ,  A61K31/704 ,  A61K31/70 ,  A61K31/35 ,  A61K38/01 ,  A23L1/305 ,  A23L1/30 ,  A61P3/06 ,  A61P3/04 ,  A61P3/10 ,  A61P9/12

CPC分类号： A61K31/704 ,  A23L33/10 ,  A23L33/11 ,  A23L33/185 ,  A23L33/22 ,  A61K31/19 ,  A61K45/06

摘要： A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene selected from the group consisting of steviol, isosteviol, glucosteviol, gymnemic acid, steviolbioside, stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E or Dulcoside A, for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. In a combination drug which also comprise a soy protein, and/or fibre and/or at least one phytoestrogen these substances of plant origin act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.